Activating mutations affecting K-Ras, N-Ras, or B-RAF have been found in 55% of sequenced colorectal cancers, suggesting that activation of the Ras/MAPK pathway plays a key role (TCGA Network, 2012). This evidence concerns the gene KRAS and colorectal cancer.